AstraZeneca, Daiichi Sankyo seek US FDA’s accelerated approval for datopotamab deruxtecan to treat advanced EGFR-mutated NSCLC ...
Esperion Therapeutics' aggressive commercialization efforts have significantly boosted retail prescriptions and broadened ...
AZN beats third-quarter estimates for earnings and sales. It raises its sales and profit outlook for 2024 for the second time ...
AstraZeneca’s earnings were boosted by its oncology, cardiovascular, respiratory and immunology (R&I), and rare disease ...
Investor's Business Daily on MSN11h
AstraZeneca Reverses As Beat And Raise Outweighs Drug Smuggling ClaimsAstraZeneca beat third-quarter expectations and lifted its guidance Tuesday, and AstraZeneca stock rose despite a criminal probe in China.
Following mixed study results, the partners have backed away from seeking broad clearance of dato-dxd in lung cancer and ...
The U.K. drugmaker also announced plans to drop another $2 billion on expanding its R&D and manufacturing footprint in the ...
Merck KGaA is shaping up to take on Daiichi Sankyo and Ono Pharma in the market for tenosynovial giant cell tumour (TGCT) ...
In closing its therapeutics division and laying off 200 people, 23andMe ended an audacious bet it made nearly a decade ago — ...
Datopotamab deruxtecan new BLA submitted for accelerated approval in the US for patients with previously treated advanced EGFR-mutated non-small cell lung cancer AstraZeneca and Daiichi Sankyo's new ...
AstraZeneca now expects 2024 revenue and core earnings per share to grow by a high-teens percentage, from a previous forecast ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback